Roy F. J. Davis

Immunexpress, Inc. engages in development of revolutionary molecular diagnostics. The firm's SeptiCyte technology quantifies specific and multiple molecular markers from the patient?s own immune system for earlier detection and severity assessment of sepsis, as well as the better timing of drugs and other therapies. The company was founded by Richard Bruce Brandon, Roslyn Brandon and Mervyn Rees Thomas in and is headquartered in